stockrowDisc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) Return on assets
Disc Medicine, Inc.'s return on assets over the twelve months to 30 June 2026 was −35.1%, down 2.6 percentage points from fiscal 2025 (−32.6%). Over the past ten years it has ranged from −490.9% (fiscal 2020) to 0.00% (fiscal 2022); the current reading is higher than 30% of that period. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −32.6% | (7.26) |
| FY2024 | −25.3% | 1.61 |
| FY2023 | −26.9% | 5.11 |
| FY2022 | −32.0% | (32.01) |
| FY2022 | 0.00% | 71.42 |
| FY2021 | −71.4% | (71.42) |
| FY2021 | 0.00% | 490.89 |
| FY2020 | −490.9% | (490.89) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 23.2% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| TNGX Tango Therapeutics, Inc. compare | −18.9% |
| IOVA Iovance Biotherapeutics, Inc. compare | −23.3% |
| RLAY Relay Therapeutics, Inc. compare | −33.7% |
| IRON Disc Medicine, Inc. | −35.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −41.5% |
| DYN Dyne Therapeutics, Inc. compare | −60.3% |
| VKTX Viking Therapeutics, Inc. compare | −73.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)